Small cell lung cancer (SCLC) is a highly fatal cancer due to early and widespread metastasis and development of resistance to chemotherapy ([Hoffman *et al*, 2000](#bib14){ref-type="other"}). Despite initial sensitivity to chemotherapy, SCLC almost invariably relapses, and the patients\' 5-year survival rate is less than 5% ([Chute, 2006](#bib6){ref-type="other"}). According to the cancer homing theory, malignant cells of different solid tumours (e.g. breast and prostate cancer) might use trafficking mechanisms of haematopoietic stem cells to reach their distinct target tissues ([Wang *et al*, 2006](#bib40){ref-type="other"}). The chemokine receptor CXCR4 (CD184) and its ligand CXCL12 (SDF-1*α*) are essential for the homing and bone marrow interaction of haematopoietic stem cells ([Peled *et al*, 1999](#bib28){ref-type="other"}, [Peled *et al*, 2000](#bib27){ref-type="other"}; [Ratajczak *et al*, 2006](#bib29){ref-type="other"}). Indeed, SCLC cell lines and primary tumour cells express high levels of CXCR4 ([Kijima *et al*, 2002](#bib16){ref-type="other"}; [Burger *et al*, 2003](#bib3){ref-type="other"}), and CXCR4 ligand CXCL12 is constitutively expressed by bone marrow stromal cells ([Muller *et al*, 2001](#bib24){ref-type="other"}). Previously, we have shown that CXCR4 mediates important functions for SCLC metastasis to stromal microenvironments, for example adhesion of SCLC cells to immobilised extracellular matrix proteins and stromal cells by activation of *β*1-integrins, leading to cell adhesion-mediated drug resistance that protects SCLC cells from chemotherapeutic treatment ([Sethi *et al*, 1999](#bib34){ref-type="other"}; [Burger *et al*, 2003](#bib3){ref-type="other"}; [Hartmann *et al*, 2005](#bib12){ref-type="other"}).

Stimulation with CXCL12 leads to activation of various pathways in SCLC cells, and CXCR4 has also been reported to activate the JAK/STAT3 pathway ([Vila-Coro *et al*, 1999](#bib39){ref-type="other"}; [Ahr *et al*, 2005](#bib1){ref-type="other"}). Signal transducers and activators of transcription (STAT) proteins are latent transcription factors that become activated by phosphorylation on a specific tyrosine residue by JAK-family kinases ([Darnell, 1997](#bib7){ref-type="other"}). Upon cytokine-induced receptor activation, JAKs phosphorylate monomeric STAT proteins, which dimerise and translocate to the nucleus in a highly regulated way leading to gene transcription ([Reich and Liu, 2006](#bib30){ref-type="other"}). In many cancers, STAT3 is constitutively activated, and aberrant STAT3 signalling is implicated as an important process in malignant transformation ([Bromberg *et al*, 1999](#bib2){ref-type="other"}) and induction of angiogenesis ([Niu *et al*, 2002](#bib25){ref-type="other"}). The tight association of STAT3 activation with transformation and tumour progression makes it an attractive molecular target for novel cancer therapeutics development and many substances have been tested for their effect on STAT3 ([Deng *et al*, 2007](#bib8){ref-type="other"}). Although a link was found between CXCR4 and STAT3 in different cells, such as haematopoietic progenitor cells ([Zhang *et al*, 2001](#bib41){ref-type="other"}) or a fibrosarcoma cell line ([Soriano *et al*, 2002](#bib36){ref-type="other"}), there are no reports on STAT3 signalling in SCLC so far. Because of previously reported links between CXCR4 and JAK/STAT signalling and potential of this pathway to provide drug targets, we were interested in whether this pathway is involved in SCLC.

In this study we demonstrate that, as shown for many tumours, STAT3 is strongly phosphorylated in tumour tissue samples from patients with SCLC in comparison to samples from patients with NSCLC (non-small-cell lung cancer). We report possible increased CXCL12-induced STAT3 phosphorylation as well as lack of CXCL12 effect on STAT3 phosphorylation depending on the cell line. Further investigating this mechanism, we showed that JAK2/STAT3 activation can be involved in anchorage-dependent cell growth but is not involved in the adhesion of SCLC cells to stromal cells.

Materials and methods
=====================

Cell culture, chemokines, antibodies, and inhibitors
----------------------------------------------------

Small cell lung cancer cell lines (NCI-H69, NCI-H82, NCI-H146, NCI-H345, NCI-H446, NCI-H510A, and NCI-N592) and the murine stromal cell line M2-10B4 were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were maintained in RPMI-1640 medium containing 10% FCS, 1% penicillin, and streptomycin (Gibco-BRL, Grand Island, NY, USA). Cell viability was determined with Trypan blue staining. Synthetic human CXCL12 and JAK2 antibodies were purchased from Upstate Biotechnology (Lake Placid, NY, USA). Antibodies against STAT3 and phospho-STAT3 (Y705) were purchased from Cell Signalling Technology Inc. (Beverly, MA, USA). Antibody against CXCR4 was purchased from R&D Systems (Wiesbaden, Germany). Antibody against CD56 was obtained from AbD Serotec (Duesseldorf, Germany). Antibodies against integrin subunits were purchased from Chemicon (Schwalbach, Germany). The inhibitor TN14003 was developed and kindly provided by N Fujii (Kyoto, Japan; original publication, MRI, *Molecular Cancer Therapeutics*, 2003). Pertussis toxin was obtained from Merck Biosciences (Darmstadt, Germany). AG490 and anti-integrin antibodies were purchased from Calbiochem (Bad Soden, Germany).

Nuclear extracts and western blotting
-------------------------------------

Small cell lung cancer cells were serum starved for 3 h before stimulation with CXCL12. Cells were preincubated with AG490 for 60 min and stimulated with CXCL12. Cells (5 × 10^6^) per sample were lysed under hypotonic conditions to spare the nuclear membrane (10 m[M]{.smallcaps} HEPES (pH 8.0), 5 m[M]{.smallcaps} KCl, 0.1 m[M]{.smallcaps} EDTA, 0.1 m[M]{.smallcaps} EGTA, 1 m[M]{.smallcaps} Na~3~VO~4~, 1 m[M]{.smallcaps} DTT, 0.5 m[M]{.smallcaps} PMSF, protease inhibitor mix ('complete\'; Roche Applied Science, Penzberg, Germany). The nuclear fraction was separated by centrifugation and was lysed subsequently (20 m[M]{.smallcaps} HEPES (pH 8.0), 400 m[M]{.smallcaps} NaCl, 1 m[M]{.smallcaps} EDTA, 1 m[M]{.smallcaps} EGTA, 2 m[M]{.smallcaps} Na~3~VO~4~, 1 m[M]{.smallcaps} DTT, 0.5 m[M]{.smallcaps} PMSF, protease inhibitor mix).

Equal amounts of nuclear fractions were separated by 10% SDS--polyacrylamide gel electrophoresis (PAGE) and transferred onto nitrocellulose membranes. Immunostaining was performed using antibodies against STAT3 or phospho-STAT3 (Y705). Bands were visualised using horseradish peroxidase-conjugated secondary antibody and the enhanced chemiluminescence system (Amersham Biosciences, Freiburg, Germany).

Co-immunoprecipitation
----------------------

Cells (5 × 10^6^) per sample were serum starved, stimulated with CXCL12, centrifuged, and resuspended in 400 *μ*l lysis buffer (20 m[M]{.smallcaps} Tris-HCl (pH 8.0), 150 m[M]{.smallcaps} KCl, 1 m[M]{.smallcaps} EDTA, 1 m[M]{.smallcaps} Na~3~VO~4~, 1 m[M]{.smallcaps} PMSF, 1% Triton X-100, protease inhibitor mix). CXCR4 antibody was added overnight. Immunoprecipitates were collected with 30 *μ*l Protein G sepharose beads (Amersham Biosciences). They were washed three times with lysis buffer and once with PBS, fractionated with SDS--PAGE and immunoblotted with a JAK2 antibody.

SCLC adhesion to immobilised collagen, fibronectin, and VCAM-1
--------------------------------------------------------------

Adhesion assays to proteins of the extracellular matrix were performed as described before ([Hartmann *et al*, 2005](#bib12){ref-type="other"}). Briefly, 96-well plates were coated with collagen type I (5 *μ*g ml^−1^), fibronectin (10 *μ*g ml^−1^), and VCAM-1 (1.3 *μ*g ml^−1^) overnight. After washing steps, CXCL12 was co-immoblised for 30 min at room temperature (8 *μ*g ml^−1^) and the wells were blocked for 60 min with 1% tissue culture BSA (Sigma, Munich, Germany) in PBS. Small cell lung cancer cells were pretreated with AG490 (100 *μ*[M]{.smallcaps}) or DMSO (0.2%) for 60 min and added to the wells in quadruplicates and allowed to adhere for 30 min at 37°C in adhesion buffer (HBSS buffered with HEPES and supplemented with 0.5% BSA). The number of adherent cells was determined using the CyQUANT Cell Proliferation Assay (Molecular Probes, Eugene, OR, USA) and fluorescence was measured by a microtiter plate fluorometer (Spectra Max Gemini XS; Molecular Devices, Munich, Germany). Five independent experiments were performed.

SCLC cell adhesion to stromal cells
-----------------------------------

The murine stromal cell line M2-10B4 was seeded the day before the assay onto 24-well plates at a concentration of 1.5 × 10^5^ cells per well in RPMI-1640 supplemented with 10% FCS. Small cell lung cancer cells were preincubated with TN14003 (100 *μ*g ml^−1^; 30 min), AG490 (100 *μ*[M]{.smallcaps}; 60 min), DMSO (0.2%; 60 min), l cell layer at a concentration of 1 × 10^6^ cells per well. After 3 h at 37°C in 5% CO~2~, the wells were washed vigorously three times from four directions with 1 ml RPMI to remove non-adhering cells. The remaining cells, including stromal cells and adhering SCLC cells, were detached in trypsin/EDTA followed by three washing steps in FACS medium (RPMI+0.5% BSA). To distinguish SCLC cells from stromal cells, we labelled them with an anti-CD56-PE antibody for 30 min at 4°C and measured them by flow cytometry (FACSCalibur; Becton Dickinson, Heidelberg, Germany). Thus, increased proportion of CD56+ cells in the total cell suspension results from pre-trypsin treatment adherent cells. Samples were analysed in duplicates and each experiment was independently performed five times.

Expression of integrin subunits and VCAM-1
------------------------------------------

Expression of integrin subunits was determined using monoclonal CD29, CD49a, CD49b, CD49c, CD49d, and CD49e antibodies and the appropriate isotype controls (Becton Dickinson). Small cell lung cancer cells were adjusted to a concentration of 10^6^ cells per ml in PBS+0.5% BSA and stained with saturated antibody concentrations for 20 min at 4°C. After washing the cells twice, integrin expression was analysed by flow cytometry.

Expression of soluble VCAM-1 in cell culture supernatants was detected by an ELISA provided by R&D Systems (Quantikine Mouse sVCAM-1 Immunoassay), according to the manufacturer\'s instructions.

Soft agar assay
---------------

Small cell lung cancer cells (1 × 10^4^) were singularised in 2 ml RPMI-1640 containing 10% FCS and 0.3% agarose. Before pouring the cells onto a bottom layer of 0.6% soft agar in 12-well plates, TN14003 (100 *μ*g ml^−1^) or AG490 (100 *μ*[M]{.smallcaps}) were added. Untreated cells and DMSO-treated cells (0.2%) were used as controls. The cells were fed three times a week with fresh medium, containing the appropriate inhibitors. Cell colonies were photographed after 2 weeks.

Immunohistochemistry
--------------------

Tissue samples of primary tumours from patients suffering from SCLC (*n*=10) and NSCLC (*n*=13) were fixed in formalin and embedded in paraffin. Sections (3 *μ*m) were dried, dewaxed in xylene, and rehydrated through graded alcohol to water. Antigen retrieval was carried out by boiling the samples at pH 6.1. Antigens were stained using the alkaline phosphatase anti-alkaline phosphatase method (Dako, Hamburg, Germany) as described by the manufacturer. Antibodies against STAT3 or phospho-STAT3 (Y705) were used at a concentration of 1 : 100.

Statistical analysis
--------------------

For statistical analysis, the paired Student\'s *t*-test for comparison of two groups was used. Analyses were performed with the statistic tool of Origin 7G (OriginLab Corporation, Northampton, MA, USA).

Results
=======

Constitutive and inducible STAT3 in SCLC cell lines
---------------------------------------------------

To assess the levels of phosphorylated STAT3 in SCLC, we prepared and examined nuclear extracts from seven unstimulated SCLC cell lines by western blot analysis using an anti-phospho-STAT3 antibody. As a control, total nuclear STAT3 was stained. We found constitutive STAT3 phosphorylation in most of the investigated cell lines, but at variable levels. The cell line NCI-H510A displayed exceptionally strong constitutive STAT3 phosphorylation whereas NCI-H69 displayed the lowest level with slight to undetectable constitutive expression ([Figure 1A](#fig1){ref-type="fig"}). As NCI-H69 and NCI-H82 are the most commonly investigated SCLC cell lines and displayed rather weak constitutive activation, we further used these two cell lines to determine whether CXCL12 is able to directly activate JAK2/STAT3 signalling pathways in SCLC cells. To do so we measured levels of tyrosine-phosphorylated STAT3 in nuclear extracts after CXCL12 treatment. STAT3 exists in different isoforms; STAT3*α* is the most commonly described so far. STAT3*α* was phosphorylated upon CXCL12 stimulation in a time-dependent manner with a maximum after 10 min, still showing a strong signal after 30 min, reduced cytosolic effect might be the result of the low representation of STAT3 in this pool ([Figure 1B](#fig1){ref-type="fig"}). CXCL12-induced tyrosine phosphorylation of STAT3 could be observed in SCLC cells lines NCI-H69, NCI-H82, NCI-H119, NCI-H173, and NCI-H446, but not in NCI-N592 ([Figure 1C](#fig1){ref-type="fig"}). High expression of CXCR4 has however been described in NCI-N592 ([Burger *et al*, 2003](#bib3){ref-type="other"}) underlying the heterogeneity of SCLC cell lines and reflecting heterogeneity among SCLC diagnosed tumours themselves.

To directly analyse the association of JAK2 with CXCR4 upon CXCL12 stimulation, we performed co-immunoprecipitation assays with NCI-H69 and NCI-H82. In both cell lines, constitutive association of JAK2 with CXCR4 was observed, however with a lower intensity for NCI-H69. Association of JAK2 with CXCR4 increased upon stimulation with CXCL12 with a maximal association observed after 15 min ([Figure 1D](#fig1){ref-type="fig"}). In contrast, NCI-H82 showed a strong constitutive association of JAK2 to CXCR4 that could not be further increased by CXCL12 stimulation. The observation of two bands of phosphorylated JAK-2 was unexpected and is likely to result from protein degradation.

Expression and functions of *β*1-integrins in SCLC cell lines NCI-H69 and NCI-H82
---------------------------------------------------------------------------------

We investigated further the differences between NCI-H69 and NCI-H82 activation focusing on another family of proteins: integrins. Integrins form a family of heterodimeric proteins (*α*- and *β-*subunits). They are cell adhesion molecules that mediate cell--extracellular matrix as well as cell--cell interactions. It has been demonstrated that *β*1-integrin signalling leading to malignant cell adhesion is involved in resistance of SCLC cells against chemotherapy ([Sethi *et al*, 1999](#bib34){ref-type="other"}). Both SCLC cell lines analysed, NCI-H69 and NCI-H82, were positive for *β*1-integrin and negative for *α*1-, *α*2-, and *α*3-integrins, but differed in expression of *α*4- and *α*5-subunits. In contrast to NCI-H69 that did not express any *α*5, NCI-H82 was positive for this subunit. Integrin *α*4 was expressed in NCI-H82 more abundantly than in NCI-H69 ([Figure 2](#fig2){ref-type="fig"}). Interestingly, *α*4-*β*1 integrin, also called VLA4 (alpha4-beta1 integrin), is known to be involved in cell-adhesion mediated drug resistance of tumours ([Sanz-Rodríguez *et al*, 2001](#bib32){ref-type="other"}).

Adhesion of NCI-H82 to VCAM-1 is dependent on JAK2
--------------------------------------------------

Previously, we have shown that immobilised CXCL12 induces VLA-4-mediated adhesion of SCLC cell lines to immobilised VCAM-1 and fibronectin, which could be inhibited by pertussis toxin and rho-kinase inhibitors ([Burger *et al*, 2003](#bib3){ref-type="other"}; [Hartmann *et al*, 2005](#bib12){ref-type="other"}). Here we investigated the influence of the JAK2/STAT3 pathway on this process. Proteins of the extracellular matrix and CXCL12 were co-immobilised on 96-well plates and the adhesion rate of SCLC cells was determined.

The cell line NCI-H82 showed strongest CXCL12-mediated adhesion to VCAM-1, which could be fully reversed by preincubation with JAK2 inhibitor AG490 ([Figure 3A](#fig3){ref-type="fig"}). Adhesion of this cell line to collagen and fibronectin was weaker and there was no influence by AG490. Significant increases by CXCL12 stimulation were reached only in presence of VCAM-1 (*P*=0.002), this induction was significantly decreased after treatment with AG490. In contrast, CXCL12 induced NCI-H69 cell adhesion to collagen (*P*=0.065) whereas CXCL12-mediated adhesion to VCAM-1 and fibronectin was lower (*P*=0.095) and significantly reduced compared to results obtained for NCI-H82 cells (*P*=0.002). This correlates to the VLA-4 expression levels of the different cell lines, and the low adhesion of NCI-H69 can be explained by the low VLA-4 expression of this cell line. Basal level of adhesion is markedly different in both cell lines. We could not detect any inhibitory influence of AG490 on CXCL12-triggered adhesion of NCI-H69 cells ([Figure 3B](#fig3){ref-type="fig"}). To compare directly the treatment effects in both cell lines, we expressed the results in function of the basal levels of adhesion obtained with control BSA treatment. Results are shown in the [Table 1](#tbl1){ref-type="table"} and illustrate observations described previously, further showing the differences after treatment by AG490 in each cell lines (shaded results).

Adhesion of SCLC cell lines to the stromal cell line M2-10B4
------------------------------------------------------------

Previously we demonstrated that VLA-4 blocking by anti-*α*4 antibody and CXCR4 blocking by the antagonist TN14003 inhibited SCLC cell adhesion to stromal cells ([Hartmann *et al*, 2005](#bib12){ref-type="other"}). TN14003 is derived from T140, a horseshoe crab self-defence peptide-derived CXCR4 antagonist; TN14003 is serum stable and more specific variant of T140 ([Tamamura *et al*, 2004](#bib38){ref-type="other"}). In addition to CXCL12, soluble VCAM-1 is secreted by M2-10B4: using ELISA we determined that at least 2.38±0.66 ng ml^−1^ VCAM-1 was present in our supernatants (four independent assays in duplicates) as already observed ([Hartmann *et al*, 2005](#bib12){ref-type="other"}). Due to the observed AG490-mediated inhibition of NCI-H82 adhesion to VCAM-1 and the detected VCAM-1 secretion of stromal cells, we investigated if AG490 treatment inhibits NCI-H69 and NCI-H82 adhesion to stromal cells. However, in the more complex environment of stromal interaction, JAK2 blockage alone was not able to inhibit the SCLC cell adhesion to the stroma, whereas CXCR4 inhibition by TN14003 was fully efficient ([Figure 4](#fig4){ref-type="fig"}), demonstrating activation of branched pathways triggered by CXCL12 binding to CXCR4.

Importance of the CXCR4 and JAK2/STAT3 pathway in anchorage-independent growth
------------------------------------------------------------------------------

The anchorage-independent growth of SCLC cells was determined in a soft agar assay ([Missale *et al*, 1998](#bib22){ref-type="other"}). In absence of inhibitors and in the DMSO control, the cells were able to build large aggregates in the soft agar during the 2-week observation period. In contrast, there was no proliferation in the presence of the CXCR4 inhibitor TN14003, which suggests a contribution for this chemokine receptor in this process. There was also a complete inhibition by the JAK2 inhibitor AG490, suggesting importance of this pathway in anchorage-independent growth ([Figure 5](#fig5){ref-type="fig"}). In the first week, both the inhibited cells and controls looked quite similar under the microscope except for the fact that the inhibited ones did not proliferate. However, after 7--10 days cells inhibited with TN14003 and AG490 began to change their morphology. They became rounder, sharper circumscribed, and finally darker in appearance than the controls.

STAT3 is phosphorylated in primary tumours from patients with SCLC
------------------------------------------------------------------

To assess the relevance of these observations in a pathophysiological context, we investigated STAT3 phosphorylation in SCLC and compared it to NSCLC. Tissue samples of primary tumours from patients suffering from SCLC (*n*=10) and NSCLC (*n*=13) were stained with anti-phospho-Tyr705 STAT3 and anti-STAT3 antibodies in immunohistochemistry. Samples from patients suffering from SCLC (10 out of 10) were found to be strongly positive for phosphorylated STAT3, whereas samples from patients suffering from NSCLC (13 out of 13) showed significantly phosphorylated STAT3 only in basal layers of the respiratory epithelia and alveolar macrophages, but not within the tumour tissue. For the detection of unphosphorylated STAT3, samples from both SCLC and NSCLC were stained equally using an anti-STAT3 antibody ([Figure 6](#fig6){ref-type="fig"}).

Discussion
==========

The JAK2/STAT3 pathway is involved in various signalling cascades, including signalling of receptor tyrosine kinases and G-protein-coupled receptors. Activation of the JAK/STAT pathway is linked to proliferation, and constitutive activation of both JAK2 and STAT3 is described to be important in malignant transformation and tumourigenesis ([Bromberg *et al*, 1999](#bib2){ref-type="other"}; [Levy and Darnell, 2002](#bib18){ref-type="other"}). STAT3 is focusing more and more interest in cancer therapy as it is often overactivated in cancer. The constitutively active JAK2 mutant V617F is found in many patients with myeloproliferative diseases ([Levine and Gilliland, 2007](#bib17){ref-type="other"}), and constitutively phosphorylated STAT3 is found in many solid tumours and haematopoietic malignancies ([Lim and Cao, 2006](#bib19){ref-type="other"}). The chemokine receptor CXCR4 was described to activate the JAK2/STAT3 pathway in different cell lines ([Vila-Coro *et al*, 1999](#bib39){ref-type="other"}; [Soriano *et al*, 2003](#bib37){ref-type="other"}; [Opdam *et al*, 2004](#bib26){ref-type="other"}; [Moriguchi *et al*, 2005](#bib23){ref-type="other"}) and the intracellular domains responsible for JAK2 binding have been discovered by mutational analysis ([Ahr *et al*, 2005](#bib1){ref-type="other"}). Until now, there has been no report on the activation of the JAK/STAT pathway in SCLC.

In this study, we demonstrate that STAT3 is strongly phosphorylated in primary tumour tissues from patients with SCLC indicating that this pathway might be relevant in pathophysiological processes involved in SCLC. In contrast to this, the primary tumour tissue samples from patients with NSCLC did not show any strong STAT3 activation within the tumour tissue. In NSCLC samples, only alveolar macrophages and basal layers of respiratory epithelia showed strongly phosphorylated STAT3, cell types already known to show phosphorylation of STAT3 due to their proliferative capacity. Reports on constitutive phosphorylation of STAT3 in some NSCLC cell lines ([Song *et al*, 2003](#bib35){ref-type="other"}) and lung adenocarcinomas ([Gao *et al*, 2007](#bib9){ref-type="other"}) are not in contrast with our observation because they reported relatively low percentages of strong phosphorylation and the STAT3 phosphorylation was mainly related to mutations in the EGFR kinase domain and IL-6 production.

Small cell lung cancer tumour and cellular models for *in vitro* investigation have been shown to be heterogeneous ([Carney *et al*, 1985](#bib4){ref-type="other"}); however, some common features can be described: all analysed SCLC cell lines showed constitutive STAT3 phosphorylation, however to various degrees. In addition to the constitutive activation of STAT3, we were able to demonstrate that stimulation of SCLC cell lines with CXCL12 increased the STAT3 phosphorylation in all the cell lines but one. Interestingly, we found only the *α*-isoform of STAT3 to be phosphorylated upon stimulation. Both isoforms are thought to have different functions and to induce transcription of different genes ([Chakraborty *et al*, 1996](#bib5){ref-type="other"}; [Maritano *et al*, 2004](#bib20){ref-type="other"}), but functional differences are poorly understood so far. Nevertheless, exclusive STAT3*α* phosphorylation after IL-6 or IL-10 stimulation has been shown in different cellular models ([Maritano *et al*, 2004](#bib20){ref-type="other"}). Previous studies that describe a CXCR4-mediated STAT3 activation do not differentiate between the isoforms so our results are a new hint that cytokine activation targets *α*-isoform phosphorylation. To focus on this point, we used two SCLC cell lines that showed only low constitutive STAT3 phosphorylation but a clearly inducible phosphorylation in response to CXCL12: NCI-H82 and NCI-H69. The association of JAK2 to CXCR4 was induced by CXCL12 in NCI-H69. In NCI-H82 cell line, the constitutive association of JAK2 and CXCR4 is stronger but cannot be further increased. This seems to go along with a stronger activation of NCI-H82 in functional assays. For example, NCI-H82 showed a higher basal adhesion level in comparison to NCI-H69, and NCI-H82 built larger aggregates in soft agar assays.

CXCR7 is a recently described second receptor for CXCL12 and was shown to promote lung cancer growth *in vivo* ([Miao *et al*, 2007](#bib21){ref-type="other"}) but this receptor might rather modulate CXCR4-mediated responses than act as an independent CXCL12 receptor ([Hartmann *et al*, 2008](#bib13){ref-type="other"}). To assess a potential involvement of CXCR7 in the results observed here, we investigated CXCR7 expression at the surface of NCI-H69, NCI-H82, and NCI-N592, with a particular interest for NCI-N592, where the lack of STAT3 activation upon CXCL12 stimulation could be explained by a CXCR7 scavenging of CXCL12. Expression was shown to be absent or very low in NCI-H82 and NCI-N592 but high in NCI-H69 (data not shown); however, consistent inhibition of CXCL12 activation in NCI-H69 by TN14003 seems to rule out any major involvement of CXCR7 in this mechanism of activation.

To further evaluate the functional relevance of the biochemical proof of CXCL12-induced activation of JAK2 and STAT3 and a constitutive STAT3 phosphorylation *in vivo*, we analysed the effect of the JAK2 inhibitor AG490 on adhesion mediated by CXCR4- and anchorage-independent cell growth. Only a few studies demonstrate an influence of JAK2 in cytokine-stimulated adhesion. One study demonstrated almost complete abrogation of CXCL12-induced adhesion of T cells to VCAM-1 by AG490 ([García-Bernal *et al*, 2005](#bib10){ref-type="other"}). In accordance with these data on haematopoietic cells, we observed a complete inhibition of the CXCL12-induced adhesion of the SCLC cell line NCI-H82 to VCAM-1 by AG490. In contrast, CXCL12-induced VCAM-1 adhesion of NCI-H69 was much lower, due to lower *α*4-integrin expression, and we could not demonstrate an AG490 influence. In addition, although the bone marrow stromal cell line M2-10B4 expresses high amounts of CXCL12 and VCAM-1, we could not abrogate SCLC adhesion to M2-10B4 by AG490. This suggests compensating mechanisms or other more dominant pathways in this complex adhesion model. Besides adhesion, anchorage-independent growth is a major function that promotes tumour growth and metastasis. Anchorage-independent growth was reported to be dependent on CXCR4 by many groups and for numerous malignancies ([Ratajczak *et al*, 2006](#bib29){ref-type="other"}; [Wang *et al*, 2006](#bib40){ref-type="other"}). We analysed anchorage-independent growth in a soft agar assay ([Missale *et al*, 1998](#bib22){ref-type="other"}), where cells proliferate without cell or surface contacts and must overcome contact inhibition. Consistently with reports on other malignancies ([Sehgal *et al*, 1998](#bib33){ref-type="other"}; [Huang *et al*, 2005](#bib15){ref-type="other"}), we demonstrate a complete inhibition of soft agar proliferation in the cell lines NCI-H69 and NCI-H82 by blocking JAK2 or CXCR4 with the inhibitors AG490 and TN14003, respectively.

Taken together, we show high constitutive STAT3 phosphorylation in primary tumour samples from patients with SCLC but not from NSCLC, and constitutive and CXCL12-dependent activation of the JAK2/STAT3 pathway in SCLC cell lines. Furthermore, we have shown here, that although STAT3 is commonly implicated in SCLC biology, at least two different upstream pathways dependent or independent of CXCR4 can be involved in its phosphorylation. This is of particular interest in drug development strategies as both CXCR4 and STAT3 antagonisms have been proposed as broad spectrum target in cancer therapy ([Wang *et al*, 2006](#bib40){ref-type="other"}; [Germain and Frank, 2007](#bib11){ref-type="other"}; [Ruffini *et al*, 2007](#bib31){ref-type="other"}). We show here that SCLC drug development should take into account CXCR4/STAT3 linkage to target more specifically the malignant cells; although JAK2/STAT3 seems to have a dominant function in anchorage-independent cell proliferation, it has a minor function in adhesive processes of SCLC cells where CXCR4 antagonists should prove more efficient. Besides CXCR4 antagonists that are currently investigated in an *in vivo* model for SCLC, STAT3 inhibitors on its own or in combination with CXCR4 inhibitors will be very interesting to consider as therapeutic option for the treatment of patients with SCLC.
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![Characterisation of JAK2/STAT3 pathway in SCLC cells. Nuclear extracts of untreated SCLC cells were analysed by western blot analysis and showed STAT3 phosphorylation at different degrees. (**A**) CXCL12-induced phosphorylation of STAT3 occurred in a time-dependent manner, as observed in western blot analysis with nuclear extracts of NCI-H69 treated with 100 ng ml^−1^ CXCL12 (**B**). All tested cell lines but NCI-N592 showed induction of STAT3 phosphorylation by CXCL12 stimulation (**C**). JAK2 was stained in a western blot analysis following co-immunoprecipitation with a CXCR4 antibody after stimulating NCI-H69 (left panel) and NCI-H82 (right panel) with 100 ng ml^−1^ CXCL12 for the indicated period of time (**D**). Each blot shown is representative for at least three independent experiments.](6605068f1){#fig1}

![Expression of integrin subunits in SCLC cell lines. Fluorescence histograms depicting the expression of *β*1-integrin (CD29) and *α*1-, *α*2-, *α*3-, *α*4-, *α*5-integrin (CD49a, CD49b, CD49c, CD49d, CD49e) subunits by SCLC cell lines NCI-H69 and NCI-H82 are shown by black lines. The respective isotype controls are represented by grey shaded histograms.](6605068f2){#fig2}

![Adhesion to extracellular matrix proteins. Relative adhesion rates of NCI-H82 (**A**) and NCI-H69 (**B**) to VCAM-1, fibronectin and collagen I measured after 30 min are shown for untreated controls, cells stimulated with co-immobilised CXCL12 (8 *μ*g ml^−1^), cells preincubated with AG490 (60 min, 100 *μ*[M]{.smallcaps}), and cells that were both preincubated with the inhibitor and stimulated by CXCL12. Error bars represent s.e.m. Differences were accepted as significant when *P*\<0.05 (^\*^), *n*=5, each experiment in quadruplicates.](6605068f3){#fig3}

![Adhesion to stromal cell line M2-10B4. NCI-H82 (**A**) and NCI-H69 (**B**) were allowed to adhere to M2-10B4 cells for 3 h after pretreatment with AG490 (100 *μ*[M]{.smallcaps}, 60 min) or TN14003 (100 *μ*g ml^−1^, 30 min), respectively, then submitted to vigorous washes to remove non-adherent cells from the medium, the whole-cell complex was then submitted to trypsinisation to put it in suspension before assessment of the proportion of each cell type by FACS (*n*=3).](6605068f4){#fig4}

![Anchorage-independent growth in soft-agar. SCLC cells NCI-H82 (**A**, **B** and **E**, **F**) and NCI-H69 (**C**, **D** and **G**, **H**) were singularised, put in a 0.3% agarose gel and observed in the absence (**A**, **C**) or presence of TN14003 (100 *μ*gml^−1^) (**E**, **G**) and AG490 (100 *μ*[M]{.smallcaps}) (**F**, **H**). Appropriate controls were done with DMSO (**B**, **D**) to rule out any involvement of this solvant in the observed results. Characteristic cell aggregates were photographed after 14 days (*n*=3).](6605068f5){#fig5}

![Representative immunohistochemical staining of primary tumour samples from 10 patients with SCLC (**A** and **C**) and 13 patients with NSCLC (**B** and **D**). Slides were stained with phospho-Tyr705-STAT3 antibody (upper row: **A** and **B**) and STAT3 antibody (inferior row: **C** and **D**), respectively.](6605068f6){#fig6}
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Data are extracted from [Figure 3A and B](#fig3){ref-type="fig"}, and represent normalization in reference to basal adhesion in presence of control BSA treatment
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